Genelux Co. (NASDAQ:GNLX – Get Free Report) major shareholder Aladar Szalay sold 7,549 shares of Genelux stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $28.46, for a total value of $214,844.54. Following the sale, the insider now directly owns 1,582,028 shares of the company’s stock, valued at $45,024,516.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Aladar Szalay also recently made the following trade(s):
- On Monday, September 18th, Aladar Szalay sold 30,292 shares of Genelux stock. The shares were sold at an average price of $23.29, for a total value of $705,500.68.
- On Wednesday, September 13th, Aladar Szalay sold 19,032 shares of Genelux stock. The stock was sold at an average price of $21.44, for a total transaction of $408,046.08.
- On Monday, September 11th, Aladar Szalay sold 32,351 shares of Genelux stock. The shares were sold at an average price of $22.22, for a total transaction of $718,839.22.
- On Thursday, September 7th, Aladar Szalay sold 12,446 shares of Genelux stock. The stock was sold at an average price of $24.37, for a total transaction of $303,309.02.
Genelux Stock Down 7.1 %
Shares of Genelux stock opened at $24.97 on Tuesday. The firm’s 50 day moving average price is $24.03 and its 200-day moving average price is $26.78. Genelux Co. has a 52-week low of $5.35 and a 52-week high of $40.98.
Institutional Investors Weigh In On Genelux
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GNLX. California State Teachers Retirement System acquired a new position in shares of Genelux during the second quarter valued at about $30,000. Tower Research Capital LLC TRC acquired a new stake in Genelux in the 1st quarter worth approximately $32,000. American International Group Inc. purchased a new stake in Genelux during the 2nd quarter worth approximately $44,000. JPMorgan Chase & Co. increased its stake in Genelux by 2,105.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock valued at $72,000 after purchasing an additional 2,105 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new position in shares of Genelux in the second quarter worth $82,000. 10.77% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, Maxim Group initiated coverage on Genelux in a research report on Tuesday, September 12th. They issued a “buy” rating and a $40.00 price target for the company.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
Featured Articles
- Five stocks we like better than Genelux
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 2 Must-Have Silicon Companies That Don’t Make Microchips
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Small Caps That Have Priced In A Hard Landing For Big Upside
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- This May Have Ended Alibaba’s Winter, But Is It Time To Buy?
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
